Team Approach to Polypharmacy Evaluation & Reduction

Status Completed

Clinical Trial Summary

In an aging population, most seniors suffer from multiple chronic conditions. When the number of medications taken is ≥5 (polypharmacy), the burden of taking so many together can do more harm than good. This study will test a program focused on medication reduction involving patient, pharmacist and physician using current technology aimed at reducing the harms of polypharmacy. Reducing the risk of adverse effects from drugs or the interactions between them involves prioritizing the most important ones according to the patient's preference and stopping those which may no longer be necessary. Reducing the dose also reduces the risk of drug side effects. Patients, aged over 69 years taking ≥5 medications, will randomly receive the program immediately or at 6 months. The program involves information gathering from the patient, medication review with the pharmacist and then a consultation with the family doctor focused on discontinuing/reducing the dose of medications where possible using a 'pause and monitor' framework to assess the need for restart. An electronic program that detects drug adverse effects and flags potentially inappropriate medications will be integrated into a clinical pathway incorporating monitoring and follow up systems. This study will examine effects on patient and health relevant outcome measures as well as patients' and clinicians' experiences of the program. The results will be used to determine whether this system can be implemented as part of routine preventative care in older adults.

Clinical Trial Description

Patients will be randomized 1:1 to receive the intervention at study start or delayed appointment 6 months later. The intervention includes initial baseline data collection from the patient including data on demographics, medications, and illness characteristics. The patient will then attend an appointment with a pharmacist to review medications appropriate for discontinuation/dose reduction, after which the patient will meet with his/her family physician to discuss patient preferences for discontinuation/dose reduction. Follow up appointments will take place at one week, 3 months and 6 months (study end). Questionnaires and a semi-structured interview will take place at the 6 month appointment. After six months, the control group will be offered the intervention. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02562352
Study type	Interventional
Source	McMaster University
Contact
Status	Completed
Phase	N/A
Start date	October 2015
Completion date	November 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02816086` - A New Interdisciplinary Collaboration Structure to Improve Medication Safety in the Elderly	N/A
Withdrawn	`NCT04893395` - Assessment of the Impact of Clinical Pharmacogenomics on Real and Potential Medication Use in Veterans	N/A
Completed	`NCT02863341` - Nursing Home Team-Care Deprescribing Study	N/A
Completed	`NCT01970774` - Medication Therapy Management With Pharmacogenetic Testing	N/A
Completed	`NCT04151797` - Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients	N/A
Completed	`NCT03154489` - Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care	N/A
Completed	`NCT03257605` - A Pharmacist Implemented Pharmacogenomics Service in the Program of All-inclusive Care for the Elderly	N/A
Not yet recruiting	`NCT06310512` - Efficacy of Pharmacist Interventions Through the "Medication Therapy Management Pathway in Hypertensive Patients"	N/A
Recruiting	`NCT02942927` - Team Approach to Polypharmacy Evaluation and Reduction	N/A
Completed	`NCT03909035` - A Collaborative Approach to Medication Reviews for Older Patients With Polypharmacy	N/A
Recruiting	`NCT03557944` - Team Approach to Polypharmacy Evaluation and Reduction (Pharmacy)	N/A
Completed	`NCT02820129` - Effectiveness of a Medication Wallet Card	Phase 1
Terminated	`NCT03202264` - Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care
Completed	`NCT03321058` - Polymedication-Check With Insight in Patients' Medication Organisation and Comprehension of Generics	N/A
Completed	`NCT02658604` - Home Medication Reviews by Pharmacists in Ontario, Canada	N/A
Withdrawn	`NCT05711771` - Medication Therapy Management (MTM) for a Medicaid Managed Care Population Within Patient-Centered Medical Homes
Recruiting	`NCT05553015` - A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)
Active, not recruiting	`NCT05278650` - Senior PharmAssist: Co-Design and Evaluation of a Toolkit to Promote Scalable Implementation	N/A
Recruiting	`NCT05351281` - Appropriate Medication Use in Dutch Terminal Care	N/A
Completed	`NCT02748148` - Implementation Study of Enhanced Medication Therapy Management in Primary Care Practice	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Team Approach to Polypharmacy Evaluation and Reduction — TAPER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms